The inflammatory chemokine CCL5 and cancer progression

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Aldinucci, Donatella ^a   Colombatti, Alfonso ^a,b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Microgravity Ageing Training Immobility Center of Excellence   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; RANTES; CCL5 PROTEIN, HUMAN; CCR5 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CLASSICAL HODGKIN LYMPHOMA; COLON CANCER; HODGKIN DISEASE; HUMAN; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL5; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, CCR5; TUMOR MICROENVIRONMENT;

EID: 84893206402     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/292376     Document Type: Review

References (103)

1. Mantovani A., Molecular pathways linking inflammation and cancer. Current Molecular Medicine 2010 10 4 369 373 2-s2.0-77953485565 10.2174/ 156652410791316968
2. Hanahan D., Coussens L. M., Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012 21 3 309 322 2-s2.0-84858590826 10.1016/j.ccr.2012.02.022
3. Kershaw M. H., Westwood J. A., Darcy P. K., Gene-engineered T cells for cancer therapy. Nature Reviews Cancer 2013 13 8 525 541
4. Jain R. K., Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. Journal of Clinical Oncology 2013 31 17 2205 2218
5. Zlotnik A., Yoshie O., The chemokine superfamily revisited. Immunity 2012 36 5 705 716
6. Candido J., Hagemann T., Cancer-related inflammation. Journal of Clinical Immunology 2013 33 supplement 1 S79 S84
7. Balkwill F. R., The chemokine system and cancer. Journal of Pathology 2012 226 2 148 157 2-s2.0-82755194789 10.1002/path.3029
8. Aldinucci D., Gloghini A., Pinto A., de Filippi R., Carbone A., The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. Journal of Pathology 2010 221 3 248 263 2-s2.0-77953534075 10.1002/path.2711
9. Meadows S. A., Vega F., Kashishian A., Johnson D., Diehl V., Miller L. L., Younes A., Lannutti B. J., PI3K δ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012 119 8 1897 1900 2-s2.0-84857549432 10.1182/blood-2011-10-386763
10. Cook J., Hagemann T., Tumour-associated macrophages and cancer. Current Opinion in Pharmacology 2013 13 4 595 601
11. + T cells in colon cancer by T-regulatory cells. Cancer Research 2012 72 5 1092 1102 2-s2.0-84857754240 10.1158/0008-5472.CAN-11-2493
12. Yang X., Hou J., Han Z., Wang Y., Hao C., Wei L., Shi Y., One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment. Cell & Bioscience 2013 3 1 5 3
13. Schlecker E., Stojanovic A., Eisen C., Quack C., Falk C. S., Umansky V., Cerwenka A., Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. The Journal of Immunology 2012 189 12 5602 5611
14. Ben-Baruch A., The tumor-promoting flow of cells into, within and out of the tumor site: regulation by the inflammatory axis of TNF α and chemokines. Cancer Microenvironment 2012 5 2 151 164 2-s2.0-83655192650 10.1007/s12307-011-0094-3
15. Karnoub A. E., Dash A. B., Vo A. P., Sullivan A., Brooks M. W., Bell G. W., Richardson A. L., Polyak K., Tubo R., Weinberg R. A., Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007 449 7162 557 563 2-s2.0-34948896045 10.1038/nature06188 (Pubitemid 47525152)
16. Allavena P., Germano G., Marchesi F., Mantovani A., Chemokines in cancer related inflammation. Experimental Cell Research 2011 317 5 664 673 2-s2.0-79952090185 10.1016/j.yexcr.2010.11.013
17. Oppermann M., Chemokine receptor CCR5: insights into structure, function, and regulation. Cellular Signalling 2004 16 11 1201 1210 2-s2.0-4444246007 10.1016/j.cellsig.2004.04.007 (Pubitemid 39165449)
18. Soria G., Ben-Baruch A., The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Letters 2008 267 2 271 285 2-s2.0-47749097074 10.1016/j.canlet.2008.03.018
19. Aldinucci D., Gloghini A., Pinto A., Colombatti A., Carbone A., The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leukemia and Lymphoma 2012 53 2 195 201 2-s2.0-84856098280 10.3109/10428194.2011.605190
20. Chenoweth M. J., Mian M. F., Barra N. G., Alain T., Sonenberg N., Bramson J., Lichty B. D., Richards C. D., Ma A., Ashkar A. A., IL-15 can signal via IL-15R α JNK, and NF- B To drive RANTES production by myeloid cells. Journal of Immunology 2012 188 9 4149 4157 2-s2.0-84860316416 10.4049/jimmunol.1101883
21. Udi J., Schuler J., Wider D., Ihorst G., Catusse J., Waldschmidt J., Schnerch D., Follo M., Wasch R., Engelhardt M., Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. British Journal of Haematology 2013 161 1 104 116
22. Appay V., Rowland-Jones S. L., RANTES: a versatile and controversial chemokine. Trends in Immunology 2001 22 2 83 87 2-s2.0-0034918334 10.1016/S1471-4906(00)01812-3 (Pubitemid 32667526)
23. Roscic-Mrkic B., Fischer M., Leemann C., Manrique A., Gordon C. J., Moore J. P., Proudfoot A. E. I., Trkola A., RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 2003 102 4 1169 1177 2-s2.0-0042237921 10.1182/blood-2003-02- 0488 (Pubitemid 36988019)
24. Ridley A. J., Schwartz M. A., Burridge K., Firtel R. A., Ginsberg M. H., Borisy G., Parsons J. T., Horwitz A. R., Cell migration: integrating signals from front to back. Science 2003 302 5651 1704 1709 2-s2.0-0344305784 10.1126/science.1092053 (Pubitemid 37505725)
25. Huang C.-Y., Fong Y.-C., Lee C.-Y., Chen M.-Y., Tsai H.-C., Hsu H.-C., Tang C.-H., CCL5 increases lung cancer migration via PI3K, Akt and NF- B pathways. Biochemical Pharmacology 2009 77 5 794 803 2-s2.0-59749090797 10.1016/j.bcp.2008.11.014
26. + ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 2012 30 10 2309 2319
27. Kato T., Fujita Y., Nakane K., Mizutani K., Terazawa R., Ehara H., Kanimoto Y., Kojima T., Nozawa Y., Deguchi T., Ito M., CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling. Cytokine 2013 64 1 251 257
28. Kim J. E., Kim H. S., Shin Y. J., Lee C. S., Won C., Lee S. A., Lee J. W., Kim Y., Kang J. S., Ye S. K., LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Experimental and Molecular Medicine 2008 40 5 514 522 2-s2.0-57349090717 10.3858/emm.2008.40.5.514 (Pubitemid 352789091)
29. Wang S.-W., Wu H.-H., Liu S.-C., Wang P.-C., Ou W.-C., Chou W.-Y., Shen Y.-S., Tang C.-H., CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS ONE 2012 7 4 2-s2.0-84859613229 10.1371/journal.pone.0035101 e35101
30. Raman D., Sobolik-Delmaire T., Richmond A., Chemokines in health and disease. Experimental Cell Research 2011 317 5 575 589 2-s2.0-79952104164 10.1016/j.yexcr.2011.01.005
31. Gao D. F., Fish E. N., 89: a role for CCL5 in breast cancer cell metabolism. Cytokine 2013 63 3 264
32. Borrello I., Can we change the disease biology of multiple myeloma? Leukemia Research 2012 36 supplement 1 S3 S12
33. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., Kido S., Oshima T., Shibata H., Ozaki S., Inoue D., Matsumoto T., Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004 104 8 2484 2491 2-s2.0-4944230728 10.1182/blood-2003-11-3839 (Pubitemid 39331851)
34. Oba Y., Lee J. W., Ehrlich L. A., Chung H. Y., Jelinek D. F., Callander N. S., Horuk R., Choi S. J., Roodman G. D., MIP-1 α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Experimental Hematology 2005 33 3 272 278 2-s2.0-13844317079 10.1016/j.exphem.2004.11.015 (Pubitemid 40261308)
35. Menu E., de Leenheer E., de Raeve H., Coulton L., Imanishi T., Miyashita K., Van Valckenborgh E., Van Riet I., Van Camp B., Horuk R., Croucher P., Vanderkerken K., Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clinical and Experimental Metastasis 2006 23 5-6 291 300 2-s2.0-33751190044 10.1007/s10585-006-9038-6
36. Roodman G. D., Choi S. J., MIP-1 alpha and myeloma bone disease. Cancer Treatment and Research 2004 118 83 100
37. Hashimoto T., Abe M., Oshima T., Shibata H., Ozaki S., Inoue D., Matsumoto T., Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1 α and MIP-1 β correlates with lytic bone lesions in patients with multiple myeloma. British Journal of Haematology 2004 125 1 38 41 2-s2.0-1842505726 10.1111/j.1365-2141.2004.04864.x (Pubitemid 38453275)
38. Terpos E., Politou M., Szydlo R., Goldman J. M., Apperley J. F., Rahemtulla A., Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 α) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology 2003 123 1 106 109 2-s2.0-0141707692 10.1046/j.1365-2141.2003.04561.x (Pubitemid 37222765)
39. Roussou M., Tasidou A., Dimopoulos M. A., Kastritis E., Migkou M., Christoulas D., Gavriatopoulou M., Zagouri F., Matsouka C., Anagnostou D., Terpos E., Increased expression of macrophage inflammatory protein-1 α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 2009 23 11 2177 2181 2-s2.0-70450245348 10.1038/leu.2009.130
40. Vallet S., Pozzi S., Patel K., Vaghela N., Fulciniti M. T., Veiby P., Hideshima T., Santo L., Cirstea D., Scadden D. T., Anderson K. C., Raje N., A novel role for CCL3 (MIP-1 α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011 25 7 1174 1181 2-s2.0-79960269049 10.1038/leu.2011.43
41. Cao Y., Luetkens T., Kobold S., Hildebrandt Y., Gordic M., Lajmi N., Meyer S., Bartels K., Zander A. R., Bokemeyer C., Kröger N., Atanackovic D., The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Experimental Hematology 2010 38 10 860 867 2-s2.0-77956581743 10.1016/j.exphem.2010.06.012
42. Abe M., Hiura K., Wilde J., Moriyama K., Hashimoto T., Ozaki S., Wakatsuki S., Kosaka M., Kido S., Inoue D., Matsumoto T., Role for macrophage inflammatory protein (MIP)-1 α and MIP-1 β in the development of osteolytic lesions in multiple myeloma. Blood 2002 100 6 2195 2202 2-s2.0-0037105599 (Pubitemid 35001256)
43. Lentzsch S., Gries M., Janz M., Bargou R., Dörken B., Mapara M. Y., Macrophage inflammatory protein 1-alpha (MIP-1 α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003 101 9 3568 3573 2-s2.0-0038386032 10.1182/blood-2002-08-2383 (Pubitemid 36857943)
44. Vallet S., Anderson K. C., CCR1 as a target for multiple myeloma. Expert Opinion on Therapeutic Targets 2011 15 9 1037 1047 2-s2.0-80051761546 10.1517/14728222.2011.586634
45. Möller C., Strömberg T., Juremalm M., Nilsson K., Nilsson G., Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003 17 1 203 210 2-s2.0-0037262287 10.1038/sj.leu.2402717 (Pubitemid 36175907)
46. Dairaghi D. J., Oyajobi B. O., Gupta A., McCluskey B., Miao S., Powers J. P., Seitz L. C., Wang Y., Zeng Y., Zhang P., Schall T. J., Jaen J. C., CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 2012 120 7 1449 1457
47. Maggio E., van den Berg A., Diepstra A., Kluiver J., Visser L., Poppema S., Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Annals of Oncology 2002 13 supplement 1 52 56 2-s2.0-0036265409 (Pubitemid 34567402)
48. Fischer M., Juremalm M., Olsson N., Backlin C., Sundström C., Nilsson K., Enblad G., Nilsson G., Expression of CCL5/RANTES by Hodgkin and reed-sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. International Journal of Cancer 2003 107 2 197 201 2-s2.0-0141634201 10.1002/ijc.11370 (Pubitemid 37152897)
49. Aldinucci D., Lorenzon D., Cattaruzza L., Pinto A., Gloghini A., Carbone A., Colombatti A., Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. International Journal of Cancer 2008 122 4 769 776 2-s2.0-38349059732 10.1002/ijc.23119
50. Niens M., Visser L., Nolte I. M., Van Der Steege G., Diepstra A., Cordano P., Jarrett R. F., Te Meerman G. J., Poppema S., Van Den Berg A., Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. British Journal of Haematology 2008 140 5 527 536 2-s2.0-38949152337 10.1111/j.1365-2141.2007.06964.x (Pubitemid 351230079)
51. Hanamoto H., Nakayama T., Miyazato H., Takegawa S., Hieshima K., Tatsumi Y., Kanamaru A., Yoshie O., Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. American Journal of Pathology 2004 164 3 997 1006 2-s2.0-1242338864 (Pubitemid 38235481)
52. Baumforth K. R. N., Birgersdotter A., Reynolds G. M., Wei W., Kapatai G., Flavell J. R., Kalk E., Piper K., Lee S., Machado L., Hadley K., Sundblad A., Sjoberg J., Bjorkholm M., Porwit A. A., Yap L.-F., Teo S., Grundy R. G., Young L. S., Ernberg I., Woodman C. B. J., Murray P. G., Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. American Journal of Pathology 2008 173 1 195 204 2-s2.0-46749136862 10.2353/ajpath.2008.070845 (Pubitemid 351947967)
53. Jundt F., Anagnostopoulos I., Bommert K., Emmerich F., Müller G., Foss H.-D., Royer H.-D., Stein H., Dörken B., Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999 94 6 2065 2071 2-s2.0-0033567914 (Pubitemid 29430423)
54. Uchihara J. N., Krensky A. M., Matsuda T., Kawakami H., Okudaira T., Masuda M., Ohta T., Takasu N., Mori N., Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1. International Journal of Cancer 2005 114 5 747 755 10.1002/ijc.20784 (Pubitemid 40344436)
55. Aldinucci D., Celegato M., Borghese C., Colombatti A., Carbone A., IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. British Journal of Haematology 2011 152 2 182 190 2-s2.0-78650385740 10.1111/j.1365-2141.2010.08497.x
56. Aldinucci D., Pinto A., Gloghini A., Carbone A., Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond. Blood 2010 115 3 746 747 2-s2.0-77449105047 10.1182/blood-2009-10-247809
57. Luboshits G., Shina S., Kaplan O., Engelberg S., Nass D., Lifshitz-Mercer B., Chaitchik S., Keydar I., Ben-Baruch A., Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Research 1999 59 18 4681 4687 2-s2.0-0033568215 (Pubitemid 29428976)
58. Niwa Y., Akamatsu H., Niwa H., Sumi H., Ozaki Y., Abe A., Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clinical Cancer Research 2001 7 2 285 289 2-s2.0-0035120421 (Pubitemid 32183031)
59. Bièche I., Lerebours F., Tozlu S., Espie M., Marty M., Lidereau R., Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clinical Cancer Research 2004 10 20 6789 6795 2-s2.0-6044230918 10.1158/1078-0432.CCR-04-0306 (Pubitemid 39383027)
60. Mi Z., Bhattacharya S. D., Kim V. M., Guo H., Talbotq L. J., Kuo P. C., Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011 32 4 477 487 2-s2.0-79953727008 10.1093/carcin/bgr009
61. +/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncology Reports 2009 21 4 1113 1121 2-s2.0-67449088106 10.3892/or-00000331
62. Velasco-Velazquez M., Jiao X., de la Fuente M., Pestell T. G., Ertel A., Lisanti M. P., Pestell R. G., CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Research 2012 72 15 3839 3850
63. Lv D., Zhang Y., Kim H. J., Zhang L., Ma X., CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cellular & Molecular Immunology 2013 10 4 303 310
64. Lin S., Wan S., Sun L., Hu J., Fang D., Zhao R., Yuan S., Zhang L., Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Science 2012 103 5 904 912 2-s2.0-84860251782 10.1111/j.1349-7006.2012.02259.x
65. Swamydas M., Ricci K., Rego S. L., Dreau D., Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adhesion & Migration 2013 7 3 315 324
66. Azenshtein E., Luboshits G., Shina S., Neumark E., Shahbazian D., Weil M., Wigler N., Keydar I., Ben-Baruch A., The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Research 2002 62 4 1093 1102 2-s2.0-0036174325 (Pubitemid 34160293)
67. Zhang Y., Lv D., Kim H. J., Kurt R. A., Bu W., Li Y., Ma X., A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Research 2013 23 3 394 408
68. Yaal-Hahoshen N., Shina S., Leider-Trejo L., Barnea I., Shabtai E. L., Azenshtein E., Greenberg I., Keydar I., Ben-Baruch A., The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clinical Cancer Research 2006 12 15 4474 4480 2-s2.0-33748061991 10.1158/1078-0432.CCR-06-0074 (Pubitemid 44297794)
69. Dehqanzada Z. A., Storrer C. E., Hueman M. T., Foley R. J., Harris K. A., Jama Y. H., Shriver C. D., Ponniah S., Peoples G. E., Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncology Reports 2007 17 3 687 694 2-s2.0-34247890015
70. Smeets A., Brouwers B., Hatse S., Laenen A., Paridaens N., Floris G., Vildiers H., Christiaens M. R., Circulating CCL5 levels in patients with breast cancer: is there a correlation with lymph node metastasis? ISRN Immunology 2013 2013 5 453561 10.1155/2013/453561
71. Yi E. H., Lee C. S., Lee J. K., Lee Y. J., Shin M. K., Cho C. H., Kang K. W., Lee J. W., Han W., Noh D. Y., Kim Y. N., Cho I. H., Ye S. K., STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells. Molecular Cancer Research 2013 11 1 31 42
72. Payne A. S., Cornelius L. A., The role of chemokines in melanoma tumor growth and metastasis. Journal of Investigative Dermatology 2002 118 6 915 922 2-s2.0-0036270898 10.1046/j.1523-1747.2002.01725.x (Pubitemid 34639168)
73. Mrowietz U., Schwenk U., Maune S., Bartels J., Küpper M., Fichtner I., Schröder J.-M., Schadendorf D., The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. British Journal of Cancer 1999 79 7-8 1025 1031 2-s2.0-0033021558 10.1038/sj.bjc.6690164 (Pubitemid 29087870)
74. Mattei S., Colombo M. P., Melani C., Silvani A., Parmiani G., Herlyn M., Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. International Journal of Cancer 1994 56 6 853 857 2-s2.0-0028324596 (Pubitemid 24102753)
75. Seidl H., Richtig E., Tilz H., Stefan M., Schmidbauer U., Asslaber M., Zatloukal K., Herlyn M., Schaider H., Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Human Pathology 2007 38 5 768 780 2-s2.0-34147149679 10.1016/j.humpath.2006.11.013 (Pubitemid 46560803)
76. Song J. K., Park M. H., Choi D.-Y., Yoo H. S., Han S. B., Yoon D. Y., Hong J. T., Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF- B and upregulation of IL-1Ra in Melanoma model. PLoS ONE 2012 7 5 2-s2.0-84860490518 10.1371/journal.pone.0033747 e33747
77. Mellado M., de Ana A. M., Moreno M. C., Martínez C., Rodríguez-Frade J. M., A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Current Biology 2001 11 9 691 696 2-s2.0-0035339270 10.1016/S0960-9822(01)00199-3 (Pubitemid 32418165)
78. Fukui R., Nishimori H., Hata F., Yasoshima T., Ohno K., Nomura H., Yanai Y., Tanaka H., Kamiguchi K., Denno R., Sato N., Hirata K., Metastases-related genes in the classification of liver and peritoneal metastasis in human gastric cancer. Journal of Surgical Research 2005 129 1 94 100 2-s2.0-27144440063 10.1016/j.jss.2005.04.030 (Pubitemid 41501860)
79. Okita K., Furuhata T., Kimura Y., Kawakami M., Yamaguchi K., Tsurama T., Zembutsu H., Hirata K., The interplay between gastric cancer cell lines and PBMCs mediated by the CC chemokine RANTES plays an important role in tumor progression. Journal of Experimental and Clinical Cancer Research 2005 24 3 439 446 2-s2.0-26244466833 (Pubitemid 41416129)
80. Kim H. K., Song K. S., Park Y. S., Kang Y. H., Lee Y. J., Lee K. R., Kim H. K., Ryu K. W., Bae J. M., Kim S., Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. European Journal of Cancer 2003 39 2 184 191 2-s2.0-0037220119 10.1016/S0959-8049(02)00596-8 (Pubitemid 36057068)
81. Cao Z., Xu X., Luo X., Li L., Huang B., Li X., Tao D., Hu J., Gong J., Role of RANTES and its receptor in gastric cancer metastasis. Journal of Huazhong University of Science and Technology-Medical Science 2011 31 3 342 347 2-s2.0-80455123684 10.1007/s11596-011-0378-3
82. Hahm K. B., Song Y. J., Oh T. Y., Lee J. S., Surh Y.-J., Kim Y. B., Yoo B. M., Kim J. H., Han S. U., Nahm K. T., Kim M.-W., Kim D. Y., Cho S. W., Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible? Journal of Biochemistry and Molecular Biology 2003 36 1 82 94 2-s2.0-0038579433 (Pubitemid 36836260)
83. Sugasawa H., Ichikura T., Tsujimoto H., Kinoshita M., Morita D., Ono S., Chochi K., Tsuda H., Seki S., Mochizuki H., Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. Journal of Surgical Oncology 2008 97 5 445 450 2-s2.0-41549105427 10.1002/jso.20984 (Pubitemid 351466389)
84. + cell-involved tumor elimination. International Journal of Cancer 2008 122 11 2535 2541 2-s2.0-41549127804 10.1002/ijc.23401 (Pubitemid 351590487)
85. Cambien B., Richard-Fiardo P., Karimdjee B. F., Martini V., Ferrua B., Pitard B., Schmid-Antomarchi H., Schmid-Alliana A., CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFR β in colorectal carcinoma. PLoS ONE 2011 6 12 2-s2.0-83755183659 10.1371/journal. pone.0028842 e28842
86. Vaday G. G., Peehl D. M., Kadam P. A., Lawrence D. M., Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006 66 2 124 134 2-s2.0-31944433180 10.1002/pros.20306 (Pubitemid 43191234)
87. Maeda K., Das D., Nakata H., Mitsuya H., CCR5 inhibitors: emergence, success, and challenges. Expert Opinion on Emerging Drugs 2012 17 2 135 145
88. Colombatti M., Grasso S., Porzia A., Fracasso G., Scupoli M. T., Cingarlini S., Poffe O., Naim H. Y., Heine M., Tridente G., Mainiero F., Ramarli D., The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS ONE 2009 4 2 e4608 2-s2.0-65349135969 10.1371/journal.pone.0004608
89. Negus R. P. M., Stamp G. W. H., Hadley J., Balkwill F. R., Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. American Journal of Pathology 1997 150 5 1723 1734 2-s2.0-0030944928 (Pubitemid 27193819)
90. Tsukishiro S., Suzumori N., Nishikawa H., Arakawa A., Suzumori K., Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecologic Oncology 2006 102 3 542 545 2-s2.0-33748445084 10.1016/j.ygyno.2006.01.029 (Pubitemid 44353649)
91. Milliken D., Scotton C., Raju S., Balkwill F., Wilson J., Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clinical Cancer Research 2002 8 4 1108 1114 2-s2.0-0036554735 (Pubitemid 35177363)
92. Madar S., Goldstein I., Rotter V., 'Cancer associated fibroblasts'-more than meets the eye. Trends in Molecular Medicine 2013 19 8 447 453
93. Schickel R., Boyerinas B., Park S.-M., Peter M. E., MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008 27 45 5959 5974 2-s2.0-53549097349 10.1038/onc.2008.274
94. Mitra A. K., Zillhardt M., Hua Y., Tiwari P., Murmann A. E., Peter M. E., Lengyel E., MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discovery 2012 2 12 1100 1108
95. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., Fujino M., A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proceedings of the National Academy of Sciences of the United States of America 1999 96 10 5698 5703 2-s2.0-13044256383 10.1073/pnas.96.10.5698 (Pubitemid 29234681)
96. Velasco-Velazquez M., Pestell R. G., The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology 2013 2 4
97. Ochoa-Callejero L., Perez-Martinez L., Rubio-Mediavilla S., Oteo J. A., Martinez A., Blanco J. R., Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS ONE 2013 8 1 e53992
98. Zhang F., Arnatt C. K., Haney K. M., Fang H. C., Bajacan J. E., Richardson A. C., Ware J. L., Zhang Y., Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents. European Journal of Medicinal Chemistry 2012 55 395 408
99. Zhang X., Haney K. M., Richardson A. C., Wilson E., Gewirtz D. A., Ware J. L., Zehner Z. E., Zhang Y., Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. Bioorganic and Medicinal Chemistry Letters 2010 20 15 4627 4630 2-s2.0-77955430866 10.1016/j.bmcl.2010.06.003
100. Zhang Y., Arnatt C. K., Zhang F., Wang J., Haney K. M., Fang X., The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents. Bioorganic & Medicinal Chemistry Letters 2012 22 15 5093 5097
101. Gallo M., de Luca A., Lamura L., Normanno N., Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Annals of Oncology 2012 23 3 597 604 2-s2.0-84857589771 10.1093/annonc/mdr159
102. Borghese C., Cattaruzza L., Pivetta E., Normanno N., De L. A., Mazzucato M., Celegato M., Colombatti A., Aldinucci D., Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. Journal of Cellular Biochemistry 2013 114 5 1135 1144
103. Schall T. J., Proudfoot A. E. I., Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nature Reviews Immunology 2011 11 5 355 363 2-s2.0-79955476625 10.1038/nri2972